Goutham Sunny, Assistant Professor at The Gujarat Cancer and Research Institute, shared a post on X:
“Tepotinib in METex14 Skipping NSCLC – VISION Trial and Beyond
Background:
- MET exon 14 skipping (METex14) occurs in ~3–4% of NSCLC cases
- Patients often have poor outcomes with standard therapies
- Tepotinib, an oral MET TKI, offers a targeted option
VISION Trial – Key Highlights:
- Robust, durable efficacy in METex14+ NSCLC
- Particularly effective in first-line setting
- Consistent benefit across subgroups: Elderly and young, Asian patients, With/without brain metastases
- Real-world evidence (RWE) supports trial data
- Long-term safety manageable with preserved HRQOL (Health-Related Quality of Life)
- Approved globally: Japan (2020), USA (2021 accelerated, 2024 full),
Mechanism:
- Selective MET inhibition blocks MET-driven signaling → halts tumor growth and spread
Clinical Use Insights:
- Tepotinib compares favorably vs chemo/IO in indirect analyses
- Best outcomes observed when used early in treatment sequence
- Guidance provided for adverse event management (e.g., peripheral edema)
Pros:
- Oral targeted therapy with durable response
- Effective even in brain metastases
- Real-world validation of efficacy
- Safe long-term with preserved QoL
- First-line use may offer optimal outcomes
Cons:
- Not curative – requires ongoing therapy
- Resistance can develop
- Side effects like edema require active management
- Limited head-to-head comparative trial data
Significance:
- Tepotinib represents a major step forward for a previously underserved NSCLC subset
- Supports biomarker-driven precision oncology
- VISION + RWE help inform optimal treatment sequencing and real-world applicability”
Title: Tepotinib in patients with MET exon 14 skipping non-small cell lung cancer
Authors: Paul K. Paik, Wade T. Iams, Hatim Husain, Richard M. O’Hara Jr., Emmanuel Adewusi, Xiuning Li
You can read the Full Article on Cancer Treatment Reviews
More posts featuring Goutham Sunny